Research & News

Evidence-based explainers on retatrutide and GLP-1 science, and a weekly roundup of peptide news with a US focus. Every article cites primary sources such as peer-reviewed journals, ClinicalTrials.gov, the FDA and company disclosures.

Latest peptide news

New article every week

News · October 19, 2026

FDA Sends Interim Peptide Compounding Policy to White House Review

FDA has sent an interim peptide compounding policy to White House review. What it may cover, what it excludes, and why retatrutide isn't part of it.

Research explainers

Research · October 15, 2026

GLP-1 vs Dual vs Triple Agonists: What the Research Shows

Semaglutide, tirzepatide and retatrutide compared: how single, dual and triple incretin agonists work, what trials found, and what is still unknown.

Research · October 12, 2026

Retatrutide Clinical Trial Results Explained (2023–2026)

Every major retatrutide trial in one place: phase 2 NEJM data, TRIUMPH-1 to TRIUMPH-4, TRANSCEND-T2D-1, side effects and the FDA timeline.